Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01255514 | Sequential High-dose Dexamethasone and Response Adopted PAD or VAD Induction Chemotherapy Followed by High-dose Chemotherapy With Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 30 | Yonsei UniversityOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT01626352 | Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy | completed | Phase 2 | 22 | SCRI Development Innovations, LLCOTHER | 1 |
| Nov 22, 2017 |
| clinicaltrials |
| NCT00577512 | 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE | completed | Phase 2 | 4 | University of ArkansasOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT01524978 | A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers | completed | Phase 2 | 208 | Hoffmann-La RocheINDUSTRY | 6 | Nov 20, 2017 | clinicaltrials |
| NCT01460940 | A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma | completed | Phase 2 | 24 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT02419118 | "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "(DARA) | completed | Phase 2 / Phase 3 | 4 | Vejle HospitalOTHER | 1 | Nov 7, 2017 | clinicaltrials |
| NCT01611259 | Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue | completed | Phase 2 | 50 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT01562977 | Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL(RGemOx) | completed | Phase 2 | 82 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Oct 30, 2017 | clinicaltrials |
| NCT02046915 | Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide(PERSPECTIVE) | completed | Phase 2 | 60 | University Hospital TuebingenOTHER | 1 | Oct 30, 2017 | clinicaltrials |
| NCT02132624 | CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial. | completed | Phase 1 / Phase 2 | 15 | Uppsala UniversityOTHER | 1 | Oct 30, 2017 | clinicaltrials |
| NCT00006184 | Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2017 | clinicaltrials |
| NCT00401817 | Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma | completed | Phase 2 | 11 | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 20, 2017 | clinicaltrials |
| NCT00899847 | Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG | completed | Phase 2 | 9 | Stanford UniversityOTHER | 1 | Oct 20, 2017 | clinicaltrials |
| NCT01239394 | Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma | completed | Phase 2 | 43 | Massachusetts General HospitalOTHER | 1 | Oct 18, 2017 | clinicaltrials |
| NCT00081939 | UARK 2003-33, Total Therapy III | completed | Phase 2 | 303 | University of ArkansasOTHER | 1 | Oct 17, 2017 | clinicaltrials |
| NCT00054353 | Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 16 | Fred Hutchinson Cancer CenterOTHER | 2 | Oct 16, 2017 | clinicaltrials |
| NCT00476047 | Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission | completed | Phase 2 | 16 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT01682044 | Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma | completed | Phase 2 | 20 | Roswell Park Cancer InstituteOTHER | 1 | Oct 9, 2017 | clinicaltrials |
| NCT01481129 | Akt Inhibitor MK2206 in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2017 | clinicaltrials |
| NCT01593410 | Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 194 | CelgeneINDUSTRY | 1 | Sep 20, 2017 | clinicaltrials |
| NCT01369849 | Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2017 | clinicaltrials |
| NCT01078142 | Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma(BERT) | completed | Phase 1 / Phase 2 | 39 | Georg Hess, MDOTHER | 1 | Sep 11, 2017 | clinicaltrials |
| NCT00410605 | Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2017 | clinicaltrials |
| NCT00511238 | Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 312 | AmgenINDUSTRY | 2 | Aug 31, 2017 | clinicaltrials |
| NCT00670631 | Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment | completed | Phase 2 | 46 | Guido TricotOTHER | 0 | Aug 31, 2017 | clinicaltrials |
| NCT01866293 | Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma | completed | Phase 1 / Phase 2 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT00073918 | Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 111 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT02013817 | CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy | completed | Phase 2 | 43 | Hoffmann-La RocheINDUSTRY | 1 | Aug 18, 2017 | clinicaltrials |
| NCT00472420 | A Study of MabThera (Rituximab) Plus Standard Chemotherapy in Patients With Previously Untreated Mantle Cell Lymphoma. | completed | Phase 2 | 48 | Hoffmann-La RocheINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | Phase 1 / Phase 2 | 184 | AmgenINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT00738374 | A Study of MabThera (Rituximab) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia. | completed | Phase 2 | 97 | Hoffmann-La RocheINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT01339572 | Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation | completed | Phase 2 | 72 | University of FloridaOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT01677286 | Safety and Effect of Doxycycline in Patients With Amyloidosis | completed | Phase 2 | 25 | Boston UniversityOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT00281983 | Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia | completed | Phase 1 / Phase 2 | 100 | German CLL Study GroupOTHER | 2 | Jul 24, 2017 | clinicaltrials |
| NCT00148317 | Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma | completed | Phase 2 | 38 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 18, 2017 | clinicaltrials |
| NCT02098109 | Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma | completed | Phase 2 | 100 | Washington University School of MedicineOTHER | 1 | Jul 18, 2017 | clinicaltrials |
| NCT00006244 | Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma | completed | Phase 2 | 36 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 12, 2017 | clinicaltrials |
| NCT01460420 | Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation(EMN-alloRIC) | completed | Phase 1 / Phase 2 | 49 | European Myeloma Network B.V.NETWORK | 4 | Jul 6, 2017 | clinicaltrials |
| NCT00058240 | Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00222105 | A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life | completed | Phase 2 | 25 | University of Kansas Medical CenterOTHER | 0 | Jul 2, 2017 | clinicaltrials |
| NCT00072514 | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies | completed | Phase 2 | 55 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 29, 2017 | clinicaltrials |
| NCT00182663 | Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant | completed | Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 26, 2017 | clinicaltrials |
| NCT02423291 | A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL(FIL_SGN01) | completed | Phase 2 | 15 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jun 26, 2017 | clinicaltrials |
| NCT01775553 | Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib | completed | Phase 2 | 13 | Ajai ChariOTHER | 1 | Jun 21, 2017 | clinicaltrials |
| NCT00473590 | A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)(AMBER) | completed | Phase 2 | 102 | Genentech, Inc.INDUSTRY | 0 | Jun 14, 2017 | clinicaltrials |
| NCT00241358 | Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 92 | Washington University School of MedicineOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT01848145 | Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia | completed | Phase 2 | 34 | SCRI Development Innovations, LLCOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT01158118 | Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors | completed | Phase 2 | 48 | Washington University School of MedicineOTHER | 1 | Jun 5, 2017 | clinicaltrials |
| NCT00724568 | Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma(RVDD) | completed | Phase 1 / Phase 2 | 74 | University of Michigan Rogel Cancer CenterOTHER | 2 | Jun 2, 2017 | clinicaltrials |
| NCT01466153 | A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 183 | MedImmune LLCINDUSTRY | 8 | May 31, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Nov 28, 2017source: clinicaltrials